Genflow Biosciences, the biotechnology company focused on developing therapies to promote longevity, has released a round-up for 2024 detailing advancement in its research programmes throughout the year and ambitious plans for the year ahead.
The company’s work on the SIRT6 gene, central to its anti-ageing research, has progressed significantly, bolstered by collaborations with leading researchers and vital support from the Belgian Government. A key development has been the partnership with Exothera SA for GMP manufacturing of their MASH (GF-1002) treatment, positioning the company to begin its first proof-of-concept study.
In their Werner Syndrome programme (GF-1003), Genflow has successfully developed a proprietary liver organoid using human cells from patients with the condition, representing a significant step forward in personalised disease modelling. This approach offers more accurate insights than traditional animal testing methods.
The company’s veterinary research has also advanced, with plans underway for a six-month life extension clinical trial for ageing dogs, conducted in partnership with Syngene. Investors are awaiting results from this study, which are expected by the end of 2025, potentially opening doors for partnerships with veterinary pharmaceutical companies.
Progress continues in their sarcopenia research (GF-1005), where collaboration with the Université libre de Bruxelles is focusing on addressing mitochondrial dysfunction through innovative cell-loading techniques.
Looking ahead to 2025, Genflow aims to build upon these achievements, with the company’s focus remaining on ‘tackling ageing’.